IN ADULTS WITH ACTIVE PSORIATIC ARTHRITIS (PsA)BASDAI RESPONSE AT WEEK 24 IN PsA PATIENTS WITH IMAGING-CONFIRMED SACROILIITIS1

The BASDAI endpoints were not adjusted for multiplicity. Therefore, statistical significance has not been established.

The BASDAI endpoints were not adjusted for multiplicity. Therefore, statistical significance has not been established.

*Included patients with sacroiliitis at baseline who had either documented imaging confirmation of sacroiliitis in the past or pelvic X-ray confirmation of sacroiliitis at screening based on investigators’ judgment of presence/absence of sacroiliitis.
BASDAI is a subject self-assessment of axial disease, which asks patients to rate their symptoms on a scale of 0 to 10; with higher scores indicating greater disease severity.
Through Week 24, patients were considered to have no improvement (change=0) after meeting treatment failure criteria.
§Through Week 24, patients were considered to be nonresponders after meeting treatment failure criteria: discontinued study agent for any reason, terminated study participation for any reason, initiated or increased the dose of DMARDs or oral corticosteroids over baseline for PsA, or initiated protocol-prohibited medications/therapies for PsA. After Week 24, treatment failure rules were not applied.
Patients with missing data were considered nonresponders.
Patients with BASDAI 0 at baseline.

The BASDAI endpoints were not adjusted for multiplicity. Therefore, statistical significance has not been established.

*Included patients with sacroiliitis at baseline who had either documented imaging confirmation of sacroiliitis in the past or pelvic X-ray confirmation of sacroiliitis at screening based on investigators’ judgement of presence/absence of sacroiliitis.
BASDAI is a subject self-assessment of axial disease, which asks patients to rate their symptoms on a scale of 0 to 10; with higher scores indicating greater disease severity.
Through Week 24, patients were considered to be nonresponders after meeting treatment failure criteria: discontinued study agent for any reason, terminated study participation for any reason, initiated or increased the dose of DMARDs or oral corticosteroids over baseline for PsA, or initiated protocol-prohibited medications/therapies for PsA. After Week 24, treatment failure rules were not applied.

Reference: 1. Data on file. Janssen Biotech, Inc.